Febuxostat sodium
Based on 13 publication(s) in Google Scholar
Febuxostat (TEI 6720) sodium is a potent, selective and non-purine xanthine oxidase (XO) inhibitor with a Ki value of 0.6 nM. Febuxostat sodium has the potential for the research of hyperuricemia and gout.
Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.
- CAS No.: 1140907-13-6
- Formule: C16H15N2NaO3S
- Masse moléculaire:338.36
-
Stockage:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Activité biologique
-
Chemical Information
- Pureté et documentation
- Références
-
Help & FAQs
Publications Citing Use of MedChemExpress (MCE) Febuxostat sodium
More- Cell Metab. 2024 Mar 5;36(3):498-510.e11. [Abstract]
- Adv Sci (Weinh). 2025 Apr;12(16):e2415041. [Abstract]
- ACS Environ Au. 2025 Aug 5;5(6):573-582. [Abstract]
- Br J Cancer. 2023 Mar;128(7):1344-1359. [Abstract]
- Anal Chem. 2025 Jun 3;97(21):11099-11109. [Abstract]
- Biochem Pharmacol. 2025 Oct:240:117120. [Abstract]
- Int J Mol Sci. 2026 Mar 14;27(6):2665. [Abstract]
- Int J Mol Sci. 2025 Dec 9;26(24):11886.
- Front Pharmacol. 2022 Jun 22:13:920643. [Abstract]
- J Biol Chem. 2019 Dec 27;294(52):20084-20096. [Abstract]
- bioRxiv. 2026 Jul 10:2026.07.06.736331.
- Universität Regensburg. 2023 Jul 19.
- University of Rijeka. 2023.
Customer Validation & Images
-
Cell Proliferation/Viability Assay
-
RT-PCR
-
Cell Imaging/Staining
-
Cell Imaging/Staining
-
WB
Activité biologique
Description
In Vitro
Febuxostat sodium displays potent mixed-type inhibition of the activity of purified bovine milk xanthine oxidase, with Ki and Ki' values of 0.6 nM and 3.1 nM respectively, indicating inhibition of both the oxidized and reduced forms of xanthine oxidase[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
In Vivo
Febuxostat sodium (3-4 mg/kg; p.o.; daily for 4 weeks) with oxonic acid (750 mg/kg; oral gavage; daily for 4 weeks) preventes renal injury in 5/6 Nx (5/6 nephrectomy) rats with and without coexisting hyperuricemia[3].
Febuxostat sodium (2.5 mg/kg; p.o.; daily for 12 weeks) inhibits plaque formation in ApoE−/− mice and reduces the levels of ROS in the aortic wall of atherosclerotic mice[4].
Febuxostat sodium (15.6 mg/kg; p.o.; once daily for 21 successive days) shows antidepressant effect by significantly reduces the immobility time in the FST in mouse[5].
Febuxostat sodium (10 mg/kg; p.o.; daily for 21 days) administration with doxorubicin caused a significant decrease in nephrotoxicity markers and inflammatory mediators, restoration of normal values of oxidative stress biomarkers and hampering the expression of renal caspase-3[6].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Essai clinique
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | 2011-05 | PHASE1 |
Chemical Information
-
CAS No. 1140907-13-6
-
Masse moléculaire 338.36
-
Formule C16H15N2NaO3S
-
SMILES
O=C(C1=C(C)N=C(C2=CC=C(OCC(C)C)C(C#N)=C2)S1)O[Na]
-
Synonyms
TEI 6720 sodium; TMX 67 sodium
-
Livraison
Room temperature in continental US; may vary elsewhere.
-
Stockage
Please store the product under the recommended conditions in the Certificate of Analysis.
Publications (13)
-
Journal Impact Factor
-
Most Recent
-
Cell Metab
ABCG2 is an itaconate exporter that limits antibacterial innate immunity by alleviating TFEB-dependent lysosomal biogenesis. [Abstract]2024 Mar 5;36(3):498-510.e11. PMID: 38181789 -
Adv Sci (Weinh)
Metabolomic and Cellular Mechanisms of Drug-Induced Ototoxicity and Nephrotoxicity: Therapeutic Implications of Uric Acid Modulation. [Abstract]2025 Apr;12(16):e2415041. PMID: 40041973 -
ACS Environ Au
Machine Learning-Assisted Recognition of Environmental Sulfur-Containing Chemicals in Nontargeted Mass Spectrometry Analysis of Inadequate Mass Resolution. [Abstract]2025 Aug 5;5(6):573-582. PMID: 41277996 -
Br J Cancer
Transcriptome analysis of newly established carboplatin-resistant ovarian cancer cell model reveals genes shared by drug resistance and drug-induced EMT. [Abstract]2023 Mar;128(7):1344-1359. PMID: 36717670 -
Anal Chem
Exposome-Scale Investigation of Cl-/Br-Containing Chemicals Using High-Resolution Mass Spectrometry, Multistage Machine Learning, and Cloud Computing. [Abstract]2025 Jun 3;97(21):11099-11109. PMID: 40401576 -
Biochem Pharmacol
Dual inhibition of EGR1/STAT3 transcriptional hubs suppresses macrophage-driven liver fibrosis: A multi-omics-guided drug repurposing strategy. [Abstract]2025 Oct:240:117120. PMID: 40623460 -
Int J Mol Sci
Genome-Wide CRISPR Screens Identify ABCG2-Mediated Drug Resistance to the Threonine Tyrosine Kinase (TTK) Inhibitor CFI-402257 in Breast Cancer. [Abstract]2026 Mar 14;27(6):2665. PMID: 41898529 -
Febuxostat sodium purchased from MedChemExpress. Usage Cited in: Int J Mol Sci. 2025 Dec 9;26(24):11886.
Febuxostat (25-200 μM; 3 h) pretreatment significantly enhanced the proliferation rate of HK-2 cells after H/R, with concentrations of 100 μM and 200 μM exhibiting the most pronounced effects.
Febuxostat sodium purchased from MedChemExpress. Usage Cited in: Int J Mol Sci. 2025 Dec 9;26(24):11886.
Febuxostat (100 μM; 3 h) significantly decreased expression levels of pro-inflammatory cytokines (TNF-α, IL-1β, IL-6) in HK-2 cells after H/R.
Febuxostat sodium purchased from MedChemExpress. Usage Cited in: Int J Mol Sci. 2025 Dec 9;26(24):11886.
Febuxostat (100 μM; 3 h) markedly reduced ROS levels in HK-2 cells after H/R.
Febuxostat sodium purchased from MedChemExpress. Usage Cited in: Int J Mol Sci. 2025 Dec 9;26(24):11886.
Pretreatment with Febuxostat (100 μM; 3 h) significantly reduced the apoptosis rate of HK-2 cells following H/R treatment.
Febuxostat sodium purchased from MedChemExpress. Usage Cited in: Int J Mol Sci. 2025 Dec 9;26(24):11886.
Pretreatment with Febuxostat (100 μM; 3 h) reversed changes induced by H/R treatment, markedly increased Bcl2 expression, and decreased expression of cleaved caspase-3 and Bax in HK-2 cells.
-
Front Pharmacol
2022 Jun 22:13:920643. PMID: 35814244 -
J Biol Chem
A technique for delineating the unfolding requirements for substrate entry into retrotranslocons during endoplasmic reticulum-associated degradation. [Abstract]2019 Dec 27;294(52):20084-20096. PMID: 31748412 -
-
-
Pureté et documentation
Références
[1]. Takano Y, et al. Selectivity of febuxostat, a novel non-purine inhibitor of xanthine oxidase/xanthine dehydrogenase. Life Sci, 2005, 76(16), 1835-1847. [Content Brief]
[2]. Sanchez-Lozada LG, et al. Effects of febuxostat on metabolic and renal alterations in rats with fructose-induced metabolic syndrome. Am J Physiol Renal Physiol, 2008, 294(4), F710-F718. [Content Brief]
[3]. Sanchez-Lozada LG, et al. Effect of febuxostat on the progression of renal disease in 5/6 nephrectomy rats with and without hyperuricemia. Nephron Physiol, 2008, 108(4), p69-p78. [Content Brief]
[4]. Nomura J, et al. Xanthine oxidase inhibition by febuxostat attenuates experimental atherosclerosis in mice. Sci Rep. 2014 Apr 1;4:4554. [Content Brief]
[5]. Karve AV, et al. Evaluation of effect of allopurinol and febuxostat in behavioral model of depression in mice. Indian J Pharmacol. 2013 May-Jun;45(3):244-7. [Content Brief]
[6]. Khames A, et al. Ameliorative effects of sildenafil and/or febuxostat on doxorubicin-induced nephrotoxicity in rats. Eur J Pharmacol. 2017 Jun 15;805:118-124. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Febuxostat sodium Related Classifications
HY-14268A Related Classifications
Powered by Bioz